Key points Despite substantial investments in harm reduction and addiction treatment, Canada’s overdose crisis persists. Even with considerable interest in improving access to addiction medicine ...

(Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results. "This quarter we continued to advance our promising neurology genomic ...

Acute pain functions as a protective signal indicating potential or actual tissue damage, whereas chronic pain, persisting ...

Discover the signs of Lyme disease that everyone must recognize, from the classic bull's-eye rash to neurological symptoms ...

Preoperative anxiety is a problem for patients and linked to worse surgical outcomes. The Canadian system needs innovative ...

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update ...

It is expected that some claimants will no longer be eligible for the daily living component of PIP following government ...

Discover 10 causes of nasal breathing difficulties from deviated septum to spray addiction, plus effective solutions for ...

Misery doesn't always manifest in loud complaints. Often, it reveals itself through subtle, quiet behaviors. This article ...

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...

New research confirms that specific herbal therapies—including turmeric, boswellia, and ashwagandha—can reduce joint ...